Physician profile
Christopher Boschen
NPI 1649568072
$3,840.87
in general payments reported to CMS, 2019-2025
18 companies · $547 in 2025
The $547 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $365 · 2021: $742 · 2022: $708 · 2023: $527 · 2024: $605 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,130.86 | 2022-2025 | Infuse, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $944.51 | 2019-2021 | |
| Coopervision INC. | $428.28 | 2022-2025 | Myday Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $270.82 | 2019-2025 | Acuvue |
| Allergan, INC. | $213.71 | 2019-2022 | |
| Sight Sciences, INC. | $154.46 | 2023-2025 | Tearcare System |
| Lkc Technologies, INC. | $137.56 | 2025 | |
| Abbvie INC. | $108.07 | 2022-2024 | |
| Abb Con-Cise Optical Group LLC | $100.01 | 2021-2024 | Spectacle Lenses, Contact Lens |
| Alcon Vision LLC | $97.11 | 2019-2024 | Precision 7 |
| Maculogix, INC. | $47.62 | 2020 | |
| Novartis Pharmaceuticals Corporation | $39.48 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $37.34 | 2024-2025 | Acthar |
| Shire North American Group INC | $32.71 | 2019 | |
| Oyster Point Pharma, INC. | $26.41 | 2022-2023 | Tyrvaya |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $25.67 | 2025 | Xdemvy |
| Lumenis, INC | $23.39 | 2021 | |
| Glaukos Corporation | $22.86 | 2024 | Idose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Boschen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.